Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ELMD 
Electromed Inc (ELMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ELMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35
1 Year Target Price $35
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.2% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 203.46M USD | Price to earnings Ratio 28.58 | 1Y Target Price 35 |
Price to earnings Ratio 28.58 | 1Y Target Price 35 | ||
Volume (30-day avg) 1 | Beta 0.47 | 52 Weeks Range 17.73 - 35.56 | Updated Date 10/17/2025 |
52 Weeks Range 17.73 - 35.56 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.78% | Operating Margin (TTM) 18.7% |
Management Effectiveness
Return on Assets (TTM) 11.64% | Return on Equity (TTM) 17.18% |
Valuation
Trailing PE 28.58 | Forward PE 23.75 | Enterprise Value 191771353 | Price to Sales(TTM) 3.18 |
Enterprise Value 191771353 | Price to Sales(TTM) 3.18 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA 17.7 | Shares Outstanding 8376147 | Shares Floating 6586164 |
Shares Outstanding 8376147 | Shares Floating 6586164 | ||
Percent Insiders 20.98 | Percent Institutions 52.45 |
Upturn AI SWOT
Electromed Inc
Company Overview
History and Background
Electromed, Inc. was founded in 1980 and is based in New Prague, Minnesota. It develops, manufactures, and markets airway clearance systems used to treat chronic respiratory conditions.
Core Business Areas
- Airway Clearance Systems: Focuses on developing and marketing the SmartVest Airway Clearance System, designed to help patients mobilize and clear retained secretions from the lungs.
- Related Products and Services: Offers a range of related products, including vests, generators, and accessories, along with customer support and training services.
Leadership and Structure
Kathleen Skarvan is the President and CEO. The company operates with functional departments including sales, marketing, R&D, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- SmartVest Airway Clearance System: The SmartVest is Electromed's primary product. It uses high-frequency chest wall oscillation (HFCWO) to loosen and thin mucus in the lungs, making it easier to cough up. Market share data is not explicitly public but is estimated to be a substantial portion of the HFCWO market. Competitors include Hillrom (now part of Baxter) with The Vest and RespirTech (now part of Philips) with the inCourage system. It accounts for the vast majority of Electromed's revenue.
Market Dynamics
Industry Overview
The market for airway clearance systems is driven by the increasing prevalence of chronic respiratory diseases such as cystic fibrosis, bronchiectasis, and COPD. The industry is also influenced by technological advancements and reimbursement policies.
Positioning
Electromed is a key player in the HFCWO segment, known for its SmartVest system. Its competitive advantages include product innovation, customer service, and targeted marketing efforts.
Total Addressable Market (TAM)
The global airway clearance systems market is estimated to be hundreds of millions of dollars annually. Electromed is positioned to capture a significant portion of this TAM through its focus on HFCWO technology.
Upturn SWOT Analysis
Strengths
- Strong brand recognition within the HFCWO market
- Proprietary SmartVest technology
- Established sales and marketing network
- Focus on customer support and training
Weaknesses
- Concentration of revenue on a single product line
- Smaller size compared to larger competitors
- Dependence on reimbursement policies
- Limited international presence
Opportunities
- Expanding into new geographic markets
- Developing new products and applications for HFCWO technology
- Increasing awareness of airway clearance therapy
- Strategic partnerships and collaborations
Threats
- Intense competition from larger medical device companies
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturns
Competitors and Market Share
Key Competitors
- BAX
- PHG
Competitive Landscape
Electromed competes with larger medical device companies that have a broader product portfolio. Electromed's advantage lies in its specialization in HFCWO technology and its strong customer relationships.
Growth Trajectory and Initiatives
Historical Growth: Electromed has experienced moderate growth in recent years, driven by increased sales of the SmartVest system.
Future Projections: Analyst estimates suggest continued growth for Electromed, driven by increasing awareness of airway clearance therapy and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new marketing campaigns, and developing new product features for the SmartVest system.
Summary
Electromed is a specialized medical device company focused on airway clearance. It has a strong product in the SmartVest and solid revenue growth. Competition in the sector is strong and Electromed is at risk with reimbursement policy changes. Electromed should continue to expand and enhance its technology to stay competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share data is estimated and may not be precise. Financial data should be independently verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Electromed Inc
Exchange NYSE MKT | Headquaters New Prague, MN, United States | ||
IPO Launch date 2010-08-13 | President, CEO & Director Mr. James L. Cunniff | ||
Sector Healthcare | Industry Medical Devices | Full time employees 177 | Website https://smartvest.com |
Full time employees 177 | Website https://smartvest.com | ||
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.